Biora's New Formulation of Its Principal Product, Emdogain, Approved in Europe and Canada.Business Editors MALMO, Sweden--(BUSINESS WIRE)--March 30, 2000 Biora's new formulation of its principal product Emdogain, named Emdogain(R)Gel, has been approved for sale in Europe by BSI BSI - British Standards Institute , British Standards British Standards are the national standards of the UK. The standards body which produces them is BSI British Standards, a division of BSI Group. It is incorporated under a Royal Charter and is formally designated as the National Standards Body (NSB) for the UK. Institution, and in Canada by Health Canada Health Canada (French: Santé Canada) is the department of the government of Canada with responsibility for national public health. Health Canada's goal is to improve Canadian life by improving Canadian longevity, lifestyle and use of public healthcare. (Sante Canada). "According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. our estimates this simplified way of using Emdogain will stimulate sales in these markets", says Biora's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Tomas Hammargren. Currently Emdogain is delivered as two components, a freeze-dried protein and a vehicle solution, which the dentist is required to mix in order to form a gel that can be drawn into a syringe and applied clinically. To simplify handling and use, Biora will launch a completely new formulation of Emdogain. With the new formulation and packaging, Emdogain(R)Gel will be delivered as a stabilized premixed gel in a prefilled syringe. Each syringe is for single use only and will be individually packaged with a sterile outer layer in order to facilitate use at the surgical field. The change in formulation, packaging and delivery eliminates preparation time for the dentist and makes Emdogain truly ready to use. The product will be launched in Europe in the beginning of April. Biora estimates that application for approval in the US market will be reviewed during spring 2000. Biora develops, manufactures and sells products for the treatment of periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where and for use in oral surgery. Using its proprietary technology and expertise, Biora aims to become a world leader in biology-based products for specialized dental therapy. Biora's American Depository Shares are listed on the Nasdaq National Market in the US (NASDAQ:BIORY) DocumentEncodingutf-8NasdaqNM:BIORY and Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. in Sweden This report may contain certain forward-looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion